@article{806f638a46e4442497266feabbc4e18a,
title = "Clinical trials, adaptability and the COVID-19 pandemic",
abstract = "Despite the impact of the COVD-19 pandemic and public health crisis on health care delivery, the GOG-Foundation has continued to prioritize the delivery of novel and state-of-the-science treatment options to patients via clinical trials.",
keywords = "Adaptability, COVID-19, Clinical trials, Gynecologic cancer, Pandemic",
author = "Eskander, {Ramez N.} and Bhavana Pothuri and Leslie Randall and David O'Malley and Brian Slomovitz and Kathleen Moore and Robert Coleman and Thomas Herzog and Monk, {Bradley J.} and Larry Copeland",
note = "Funding Information: Dr. Coleman reports consulting and/or research support funding from AstraZeneca, Merck, Tesaro/GSK, Medivation, Clovis, Gamamab, Genmab, Roche/Genentech, Janssen, Agenus, Regeneron and OncoQuest. Funding Information: Dr. Randall reports grants, personal fees and non-financial support outside of the submitted work from BluPrint Oncology, AstraZeneca, Clovis, Novocure, GOG Foundation, Merck, Mersana, Agenus, Tesaro/GSK, Genentch/Roche, On Target Laboratories, Pfizer, Aivita Biomedical, Akeso Biopharma, and GEICO. Publisher Copyright: {\textcopyright} 2020 The Author",
year = "2021",
month = feb,
doi = "10.1016/j.gore.2020.100680",
language = "English (US)",
volume = "35",
journal = "Gynecologic Oncology Case Reports",
issn = "2211-338X",
publisher = "Elsevier BV",
}